Abstract. BELLO, Ariel et al. Splenic marginal zone lymphoma. Acta Med Colomb [online]. , vol, n.1, pp ISSN Non-Hodgkin. Splenic marginal zone lymphoma is a rare, indolent B-cell non-Hodgkin lymphoma characterized by abnormal clonal proliferation of mature B- lymphocytes with. Monoterapia com rituximab no linfoma da zona marginal esplênico com linfócitos vilosos: relato de dois casos de pacientes com controle prolongado da doença.
|Published (Last):||22 March 2010|
|PDF File Size:||9.29 Mb|
|ePub File Size:||12.40 Mb|
|Price:||Free* [*Free Regsitration Required]|
The Integruppo Italiano Linfomi IIL carried out a study to assess the outcomes of splenic marginal zone lymphoma and to identify prognostic factors in patients. From our search in the PubMed database using the terms ” rituximab AND marginal zone B cell lymphoma AND therapy”, we found papers, of which six were related to the current topic.
Treatment of these cases and second-line therapy for relapsed patients have not been yet identified. margina
Watch and wait con vigilancia cada meses: Mechanism of activation and biological role of the c-myc oncogene in B-cell lymphomagenesis. Hepatitis C virus and autoimmune manifestations, such as autoimmune hemolytic anemia and autoimmune thrombocytopenia, could be associated.
Linfoma esplénico de la zona marginal:
At this time, the patient was referred to our center, and we decided to avoid chemotherapy and start rituximab as a zpna agent, because she presented with a creatinine level slightly over the normal range. She had slight splenomegaly. Patients espelnico condition progresses even after splenectomy, or those who have a more aggressive tumor, may be successfully managed with chemotherapy, using alkylating agents or purine analogues.
Splenic marginal zone lymphoma with and without villous lymphocytes.
Disease definition Splenic marginal zone lymphoma is a rare, indolent B-cell non-Hodgkin lymphoma characterized by abnormal clonal proliferation of mature B-lymphocytes with involvement in the spleen, bone marrow and, frequently, the blood. RT PCR para t 11; BCL10 expression in normal and neoplastic lymphoid tissue.
February 8, Last submission: The current WHO classification of lymphoid neoplasms represents a major step forward in our understanding of these tumours. This item has received. A clinicopathological study of 13 cases. Detection by the fluorescence in situ hybridization technique of MYC translocations in paraffin-embedded lymphoma biopsy samples.
We conclude that this treatment is safe and well tolerated and is able to induce a substantial number of responses. Cytogenetic studies in seventy-six cases of B-chronic lymphoproliferative disorders.
LEZM – Linfoma Esplénico de la Zona Marginal
Si neutropenia G-CSF o profilaxis con ciprofloxacino. All articles are subjected to a rigorous process of revision in pairs, and careful editing for literary and scientific style. The bone marrow was not compromised.
The role of rituximab as maintenance therapy, in order to prolong the time that elapses until progression occurs, still needs to be confirmed. Detailed information Professionals Review article Deutsch You can change the settings or obtain more information by clicking here.
In conclusion, with the use of readily available factors, this prognostic index may be an effective tool for evaluating the need for treatment and the intensity of therapy in an individual patient.
Only comments seeking to improve the quality and accuracy of information on the Orphanet website oa accepted. Summary and related texts. Low dose 2CdA schedule activity in splenic marginal zone lymphomas.
One out of the three partial responders have a persistent response. Splenic small B-cell lymphoma with predominant red pulp involvement: Continuing navigation will be considered as acceptance of this use.
Procesos linfoproliferativos no Hodgkin de células B
The median clinical remission interval was 46 months. It is still unclear whether these patients should undergo cytotoxic chemotherapy, considering they have now a relapsed lymphoma which is theoretically more aggressiveor whether they should be spared from treatments of greater toxicity, given that their disease usually develops with a more indolent course, even when it recurs.
Es una enfermedad moderadamente agresiva, no curable. It needs to be emphasized that the evidence to support this approach is based only on case reports, since there are no randomized clinical trials on this subject. Non-Hodgkin’s Lymphoma Classification Project. Documents Flashcards Grammar checker.
From Monday to Friday from 9 a. Ten of the 11 patients responded to rituximab and five of them remained progression-free after a median follow-up of 58 months. Because the patient refused to receive cytotoxic therapy, monotherapy with rituximab was proposed.
Patients’ median age was 57 years range, Primary nodal marginal zone lymphomas of splenic and MALT type. The immunochemotherapy regimen was well tolerated and all patients exhibited complete remission. However it carries significant complications, especially in elderly patients.
The aim of any lymphoma classification is to provide an international language allowing communication. In this setting, because of the low toxicity profile of rituximab, this monoclonal antibody has emerged as a convenient alternative for treating patients who refuse to undergo splenectomy or who are clinically unfit for a surgical procedure.
The BCL6 gene in B-cell lymphomas with 3q27 translocations is expressed mainly from the rearranged allele irrespective of the partner gene. Se suelen identificar Cuerpos de Dutcher inclusiones nucleares fig. Transformation of follicular lymphoma to diffuse large cell lymphoma is associated with a heterogeneous set of DNA copy number and gene expression alterations.
The present case indicates that treatment with fludarabine is effective for SLVL and recommended as the first-line therapy for elderly patients and those with an aggressive form of the disease.